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Pulmonary arterial hypertension (PAH) is frequently complicated by sleep disordered
breathing (SDB), and previous studies have largely focused on hypoxemic SDB. Even
though nocturnal hypercapnia was shown to exacerbate pulmonary hypertension, the clini-
cal significance of nocturnal hypercapnia among PAH patients has been scarcely
investigated.
Method
Seventeen patients with PAH were identified from 246 consecutive patients referred to
Kyoto University Hospital for the evaluation of lung transplant registration from January
2010 to December 2017. Included in this study were 13 patients whose nocturnal transcuta-
neous carbon dioxide partial pressure (PtcCO2) monitoring data were available. Nocturnal
hypercapnia was diagnosed according to the guidelines of the American Academy of Sleep
Medicine. Associations of nocturnal PtcCO2 measurements with clinical features, the find-
ings of right heart catheterization and pulmonary function parameters were evaluated.
Results
Nocturnal hypercapnia was diagnosed in six patients (46.2%), while no patient had daytime
hypercapnia. Of note, nocturnal hypercapnia was found for 5 out of 6 patients with idiopathic
PAH (83.3%). Mean nocturnal PtcCO2 levels correlated negatively with the percentage of
predicted total lung capacity (TLC), and positively with cardiac output and cardiac index.
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Conclusion
Nocturnal hypercapnia was prevalent among advanced PAH patients who were waiting for
lung transplantation, and associated with %TLC. Nocturnal hypercapnia was associated
with the increase in cardiac output, which might potentially worsen pulmonary hypertension
especially during sleep. Further studies are needed to investigate hemodynamics during
sleep and to clarify whether nocturnal hypercapnia can be a therapeutic target for PAH
patients.
Introduction
Pulmonary hypertension (PH) is a syndrome resulting from multiple clinical conditions and
disorders. Pulmonary arterial hypertension (PAH), corresponding to Group 1 of the Nice clas-
sification, is a group of diseases directly affecting pulmonary arterial resistance. PAH includes
idiopathic PAH (IPAH), congenital heart disease-associated PH and connective tissue disease-
associated PH [1, 2].
PAH is the fourth leading cause of the necessity for lung transplantation worldwide [3].
Although the recent development of medications to lower pulmonary arterial pressure (PAP)
has substantially improved the prognosis of PAH [4], about 10% of PAH patients were
reported to die within one year after the diagnosis [5]. The prognosis is especially poor for
those with persistently high PAP despite extensive therapy [6], and considered for the candi-
dates of lung transplantation [2]. While lung transplantation has been established as a thera-
peutic option for advanced PAH, interventions that can improve the hemodynamics are also
required for those on the waiting-list for lung transplantation.
Disturbance in gas exchange is one of the major disorders in PH patients [2]. Previous stud-
ies showed that hypoxia and hypercapnia worsen PAH [7]. Indeed, hypoxia causes constriction
of the pulmonary artery and increases PAP [8]. Similarly, hypercapnia also contributes to the
elevation of PAP, and it has been proposed that increases in pulmonary vascular resistance
(PVR) and cardiac output (CO) additively work as the pathogenesis of PAH(11–13). In addi-
tion, respiratory acidosis due to high CO2 partial pressure can also cause PAP escalation [9,
10].
While the disturbance in pulmonary function causes alveolar hypoventilation and chronic
CO2 retention, sleep disordered breathing (SDB), including sleep apnea syndrome (SAS), may
result in nocturnal hypoventilation and hypercapnia [11]. Previous studies suggested that SAS
as well as nocturnal hypercapnia were associated with the escalation of PAP [12–14] and that
positive pressure ventilation during sleep could lower daytime PAP [15–17]. In addition, SAS
is a common morbidity for patients with PAH [18], thus nocturnal hypercapnia due to SDB
may play a significant role in the pathogenesis of PAH. However, thus far no study has investi-
gated the associations between nocturnal hypercapnia and clinical indices for refractory PAH
patients so far.
The objective of this study is to evaluate the clinical relevance of nocturnal hypercapnia in
advanced PAH being considered for lung transplantation. We hypothesized that nocturnal
hypercapnia would be associated with worsened PH in these most severely affected patients.
We evaluated nocturnal hypercapnia by using a transcutaneous carbon dioxide partial pres-
sure (PtcCO2) monitoring system, and investigated the associations of nocturnal hypercapnia
with clinical and hemodynamic parameters.
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Materials and methods
Study patients
We reviewed 246 consecutive cases that were referred to Kyoto University Hospital for the
evaluation of suitability for lung transplantation from January 2010 to December 2017. We
identified 17 patients who were classified as having Group 1 PH according to the current
guidelines [2]. The diagnosis of PAH was made at the primary hospitals, and confirmed at
Kyoto University. We then identified 13 patients whose pre-operative whole-night PtcCO2
monitoring data were available and performed further analyses. We included patients irrespec-
tive of whether they were ultimately enrolled as candidates for lung transplantation. For all
included cases right heart catheterization was performed, and those with post-capillary PH or
thromboembolic pulmonary hypertension was excluded. High-resolution computed tomogra-
phy was performed in all cases and patients with any comorbid lung diseases that might result
in PH were denied as study patients. Written informed consent was obtained from most of the
study participants. For the patients whose contact information was lost, we announced the
conduct of this study on our institutional website and asked to contact us if they disagreed
with our data access. The Kyoto University Hospital Institutional Review Board approved this
study including ethical policy for data access (R1287).
Continuous evaluation of PtcCO2
According the manual of the American Academy of Sleep Medicine (AASM), we used PtcCO2
as a surrogate measurement of PaCO2 [19]. We utilized the TOSCA device (TOSCA measure-
ment system and TOSCA 500 monitor, Linde Medical Sensors, Basel, Switzerland) because it
has been demonstrated to have good accuracy in adult patients compared with blood gas anal-
ysis [20–22]. SpO2 was simultaneously monitored. Nocturnal hypercapnia was diagnosed
according to the guidelines of AASM; i.e. PtcCO2 >55 mmHg for�10 minutes or an increase
in PtcCO2�10 mmHg in comparison to an awake supine value exceeding 50 mmHg for�10
minutes [23]. Daytime hypercapnia was diagnosed in cases in which PaCO2 evaluated by day-
time arterial blood gas (ABG) sampling at rest was higher than 45 mmHg. ABG data from
samples obtained at the nearest day to the PtcCO2 monitoring were utilized for the analysis.
Data collection and analysis
The clinical data were retrospectively collected from medical records. Patients were grouped
according to the presence or absence of nocturnal hypercapnia. Analyzed parameters included
results of right heart catheterization, pulmonary function tests and laboratory tests. The corre-
lations between right heart catheter parameters and mean nocturnal PctCO2 were also evalu-
ated. Data from the nearest day to the PtcCO2 monitoring were utilized for the analyses.
Statistical analyses
Data are summarized as median (range) and number (percentage). We considered that the
number of study patients was too small to determine whether each parameter followed normal
distribution or not, therefore we employed non-parametric statistics for analyses. Fisher’s
exact test, Mann-Whitney’s U test and Spearman’s rank correlation test were used as appropri-
ate. EZR (Saitama Medical Centre, Jichi Medical University, Saitama, Japan) [24], which is a
graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria),
or GraphPad Prism version 7.00 for Windows (GraphPad Software, La Jolla, CA, USA, www.
graphpad.com) was used for statistical analyses. A P-value less than 0.05 was determined to be
statistically significant.
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Results
Characteristics of patients with and without nocturnal hypercapnia
Thirteen PAH patients with available overnight PtcCO2 measurements were identified for this
study. Among them, eight patients were registered for cadaveric lung transplantation, three
patients received living-donor lung transplantation, one patient died shortly after the evalua-
tion before the registration and the other patient was not registered due to an improved
response to medical treatment. As shown in Table 1, six out of 13 patients (46.2%) had noctur-
nal hypercapnia (representative test results are presented in S1 Fig). There were no differences
between patients with and without nocturnal hypercapnia in terms of age, sex, body mass
index or blood BNP level. The treatment procedure was also similar, although the introduction
of intravenous epoprostenol treatment was relatively frequent in patients with nocturnal
hypercapnia (86.6% vs. 28.6%, P = 0.103). Two patients had received prior chest surgery, both
of which were repair surgery for congenital heart diseases, neither of these patients exhibited
nocturnal hypercapnia.
All patients were receiving long-term oxygen therapy. Differences in the rates of death and/
or transplantation were not significant.
Notably, of the 6 patients with nocturnal hypercapnia, 5 had IPAH (83.3%). A comparison
of the mean and maximum PtcCO2 levels at night between IPAH patients and non-IPAH
patients showed that mean and maximum PtcCO2 at night were significantly higher among
the IPAH patients (Fig 1).
Parameters of respiratory status and pulmonary function in patients with
and without nocturnal hypercapnia
We next investigated the characteristics of the respiratory status and pulmonary function of
patients with and without nocturnal hypercapnia (Table 2). Seven of the 13 patients had a
decrease in %FVC <80%, while there were no significant differences in %FVC, %FEV1 and %
DLco between the two groups. On the other hand, we found that the %TLC and %PEF in the
nocturnal hypercapnia group was significantly lower than in the group without nocturnal
hypercapnia; also patients with nocturnal hypercapnia had a significantly higher mean and
maximum PtcCO2. All the patients were prescribed long-term oxygen therapy including usage
during sleep. However, an increase in 3%ODI, which is generally regarded as a representative
indicator of SDB, was rarely observed in either group. Daytime PaCO2 was equivalent in both
groups, and daytime hypercapnia was not observed in any patient in the present study.
We further investigated whether mean PtcCO2 was associated with pulmonary function
indexes. We found negative correlations between mean PtcCO2 at night and %TLC (Fig 2).
Correlations between nocturnal hypercapnia and hemodynamic
parameters
Among the parameters of hemodynamic status, we found that the patients with nocturnal
hypercapnia had a significantly higher levels of cardiac output (CO) and cardiac index (CI)
measured by right heart catheterization (P = 0.012 and P = 0.015, respectively). However, there
were no significant differences between groups in other right heart catheter parameters such
as mean, systolic and diastolic PAP, mean PCWP and PVR (Table 3). Investigation of the cor-
relations between the mean PtcCO2 at night and the CO and CI showed strong correlations
(Fig 3A and 3B).
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Discussion
In the present study nocturnal hypercapnia was observed in nearly half of the PAH patients, as
well as in most of those with IPAH, who were considered for lung transplantation. Mean
PtcCO2 at night correlated negatively with %TLC. Higher PtcCO2 was associated with
increased CO and CI. This is the first study to investigate the clinical significance of nocturnal
hypercapnia in PAH patients.
Nocturnal hypercapnia results mainly from alveolar hypoventilation during sleep. The
pathogenesis of nocturnal hypercapnia is comprised of the impairment of pulmonary function
and an insufficient response against hypoxia/hypercapnia [11]. Although obesity hypoventila-
tion syndrome is a major cause of nocturnal hypercapnia [11], the BMI in the majority of the
current study patients was lower than normal (18.5 kg/m2). Previously it was revealed that a
low BMI affects the respiratory muscle mass, which results in the impairment of muscle per-
formance [25] and a proportional decline in respiratory pressure [26]. In the present study,
low values for %FVC, %TLC and %PEF were the most distinct features of nocturnal hypercap-
nia. Total lung capacity is determined by lung elastic recoil, chest wall elastic recoil and inspi-
ratory muscle power, whereas expiratory muscle power and airway obstruction largely affects
PEF [27]. Given that in this study restrictive and obstructive pulmonary diseases were denied
by computed tomography and pulmonary function test, and lung and chest wall elastic recoils
are not changed in patients with PAH in general, the decrease in %TLC and %PEF would be
due to a decline in inspiratory and expiratory muscle power, respectively [27]. Other potential
factors for the restriction of chest movement, such as previous thoracic surgery or skin stiffness
Table 1. Background data on study patients.
Nocturnal hypercapnia (-) Nocturnal hypercapnia (+) P-value
Number 7 6
Age 31.00 [12.00, 59.00] 26.00 [14.00, 53.00] 0.568
Male sex (%) 3 [42.9] 0 [0.0] 0.192





Previous thoracic surgery 2 0 0.462
Nasal 0xgen supplementation (L/min) 2.00 [1.00, 7.00] 2.00 [1.00, 4.00] 0.348
Body mass index 18.37 [15.35, 25.57] 18.19 [13.29, 30.32] 0.886
Treatment
Number of oral anti-PH medication 2.00 [1.00, 4.00] 2.00 [1.00, 3.00] 0.879
Diuretics usage 6 [85.7] 5 [83.3] >0.99
IV Epoprostenol usage 2 [28.6] 5 [83.3] 0.103
IV Epoprostenol dose (ng/kg/min) 35.5 [0.9, 70] 51.0 [45, 200.0] 0.571
Laboratory tests
BNP (pg/ml) 98.70 [11.90, 586.90] 127.90 [10.10, 170.50] 0.465
Hemoglobin (g/dl) 12.00 [10.00, 24.70] 11.30 [9.30, 19.90] 0.431
Lung transplantation 2 [28.6] 3 [50.0] 0.592
Death 2 [28.6] 0 [0.0] 0.462
Data are presented as number [%] or median [range]. Mann-Whitney’s U-test or Fisher’s exact test was used for statistical analyses. IPAH: idiopathic pulmonary arterial
hypertension, PVOD: pulmonary venous occlusive disease.
https://doi.org/10.1371/journal.pone.0227775.t001
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due to systemic sclerosis, were only found in the patients without nocturnal hypercapnia, sug-
gesting that these factors did not largely affect nocturnal hypercapnia in this study. Although
we could not investigate muscle mass or muscle power directly, these pulmonary function data
Fig 1. Mean PtCO2 in non-IPAH and IPAH patients. Box plots indicating mean (A) or maximum (B) values of PtcCO2 among IPAH (n = 6) or non-IPAH (n = 7)
patients. Whiskers indicate the highest and lowest values. P-values were calculated using Mann-Whitney’s U-test. �: P< 0.05, ��: P< 0.01. IPAH: idiopathic pulmonary
arterial hypertension.
https://doi.org/10.1371/journal.pone.0227775.g001
Table 2. Pulmonary function tests and blood gas indices.
Nocturnal hypercapnia (-) Nocturnal hypercapnia (+) P-value
Number 7 6
Capnometer measurements
3%ODI (per hour) 0.35 [0.00, 2.95] 1.38 [0.12, 12.02] 0.198
Max PtcCO2 (mmHg) 48.00 [39.00, 54.00] 73.50 [59.00, 75.00] 0.003
Mean PtcCO2 (mmHg) 42.41 [35.27, 47.32] 50.70 [47.52, 65.36] 0.003
Pulmonary Function tests
%FVC 85.05 [56.00, 96.30] 75.20 [38.10, 88.90] 0.173
%FEV1 79.80 [59.80, 87.20] 65.20 [43.00, 87.10] 0.109
%DLco 63.73 [31.57, 90.48] 57.38 [32.74, 80.26] 0.715
%TLC 94.10 [88.40, 112.10] 84.35 [56.40, 92.20] 0.018
%PEF 95.30 [78.80, 111.90] 78.05 [70.20, 88.20] 0.015
Daytime arterial blood gas
PaO2 (mmHg) 87.60 [41.00, 121.20] 75.65 [56.50, 117.80] 0.775
PaCO2 (mmHg) 35.60 [28.70, 41.60] 38.60 [32.80, 44.30] 0.224
HCO3
- (mEq/l) 22.50 [19.70, 27.10] 25.35 [21.50, 27.00] 0.199
Data are presented as median [range]. Mann-Whitney’s U-test was used for statistical analyses.
FVC: forced vital capacity, FEV1: , DLco: , TLC: total lung capacity, PEF: peak expiratory flow, ODI: Oxygen desaturation index, PtcCO2: transcutaneous carbon dioxide
partial pressure.
https://doi.org/10.1371/journal.pone.0227775.t002
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imply that the lowered respiratory muscle power associated with a low BMI were candidate
mechanisms for nocturnal hypercapnia. Recently, decreased muscle mass due to sarcopenia
was shown to be frequent among lung transplantation candidates and constitute a risk factor
for a poor prognosis [28]. In addition, inspiratory muscle power is substantially reduced dur-
ing sleep, especially during rapid eye movement sleep [29]. Therefore, the reduction in minute
Fig 2. Associations between PtCO2 and pulmonary function test indices. Scatter plots showing the correlations between mean PtcCO2 and %FEV1 (A), %FVC (B), %
DLco (C), %TLC (D) or %PEF (E). Each dot represents one patient. Spearman’s rank correlation test was used for statistical analysis. For one patient no pulmonary
function data were available, and for two patients DLco and TLC data were not available. �: P< 0.05. FEV1: forced expiratory volume in one second, FVC: forced vital
capacity, DLco: diffusing capacity for carbon monoxide, TLC: total lung capacity, PEF: peak expiratory flow.
https://doi.org/10.1371/journal.pone.0227775.g002
Table 3. Right heart catheter measurements in the patients with and without nocturnal hypercapnia.
Nocturnal hypercapnia (-) Nocturnal hypercapnia (+) P-value
Number 7 6
Right heart catheter measurements
mean PAP (mmHg) 54.00 [46.00, 82.00] 57.00 [35.00, 92.00] 0.774
systolic PAP (mmHg) 88.00 [62.00, 101.00] 95.00 [52.00, 142.00] 0.568
diastolic PAP (mmHg) 30.00 [15.00, 66.00] 29.00 [23.00, 70.00] 0.886
mean PCWP (mmHg) 9.00 [6.00, 25.00] 11.00 [10.00, 13.00] 0.126
PVR (mmHg/L/min) 10.32 [4.66, 23.27] 6.31 [4.07, 24.05] 0.317
Cardiac Index (L/min/m2) 2.66 [1.98, 3.24] 4.26 [2.66, 6.97] 0.012
Cardiac Output (L/min) 3.97 [2.51, 5.25] 6.54 [3.41, 8.43] 0.015
Data are presented as median [range]. Mann-Whitney’s U-test was used for statistical analyses.
PAP: pulmonary arterial pressure, PCWP: pulmonary capillary wedge pressure, PVR: pulmonary vascular resistance.
https://doi.org/10.1371/journal.pone.0227775.t003
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ventilation which results in sleep-related hypoventilation might represent an early stage of
chronic hypoventilation syndrome [11]. Indeed, the low values for %TLC in the study patients
were associated with an elevation in mean PtcCO2, which suggests relationships between
impairment of pulmonary function due to the respiratory muscle dysfunction in IPAH
patients and nocturnal hypercapnia. In addition to the impairment in pulmonary function,
previous studies suggested that in PAH patients the cerebral microvascular blood flow
response against PaCO2 elevation is suppressed, thereby ameliorating the stimuli to breathe
[30]. The integration of these factors may contribute to the high prevalence of nocturnal
hypercapnia among IPAH patients. On the other hand, in the present study, there were no sig-
nificant differences in BMI between patients with and without nocturnal hypercapnia, or
between IPAH and non-IPAH patients. These results suggest that other factors had contrib-
uted to the impairment of muscle power especially in patient with nocturnal hypercapnia or
IPAH patients. Therefore, further study is required to investigate the underlying pathophysiol-
ogy of nocturnal hypercapnia in PAH patients.
In contrast to the high prevalence of nocturnal hypercapnia, daytime hypercapnia was not
observed in any study patient, indicating that alveolar hypoventilation among PAH patients is
largely limited during sleep. Recently, it was reported that noninvasive ventilation (NIV) can
improve nocturnal hypercapnia in patients with nocturnal hypercapnia without daytime
hypercapnia [31]. In addition, while alveolar hypoventilation may accompany low values for
partial pressure of oxygen, the elevation of 3%ODI was rarely observed among the study
patients, presumably because of treatment with oxygen supplementation. These results suggest
that the assessment of either the daytime PaCO2 level or nocturnal SpO2 level is not sufficient
to predict the complication of nocturnal hypercapnia in PAH patients, which highlights the
significance of PtcCO2 monitoring at night.
Hypoxia is regarded as a significant factor in the progression of PAH and careful monitor-
ing is generally performed [2]. Indeed, in the present study oxygen supplementation was intro-
duced to all study participants and oxygen desaturation was rarely observed. On the other
hand, the clinical significance of nocturnal hypercapnia/hypocapnia in PAH patients has been
Fig 3. Associations between PtcCO2 and cardiac output or index. Scatter plots showing the correlations between mean PtcCO2 and cardiac output (A) or cardiac
index (B). Each dot represents one patient. Spearman’s rank correlation test was used for statistical analysis. ��: P< 0.01.
https://doi.org/10.1371/journal.pone.0227775.g003
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scarcely investigated. Physiologically, hypercapnia contributes to the escalation of PAP
through several mechanisms. First, elevation of PaCO2 directly induces the constriction of the
pulmonary vasculature, thereby increases PVR [8]. Second, ventilatory acidosis resulting from
rapid elevation of PaCO2 also increases PVR [9]. Third, elevated PaCO2 increases CO, which
causes the escalation of PAP [10]. Even though nocturnal hypercapnia is reversible, prolonged
and repeated exposure of the above factors eventually enhances stiffness of pulmonary vessels
and results in an increase in PVR. Indeed, obesity hypoventilation syndrome is often compli-
cated with PH [13], and NIV treatment during sleep can lower daytime PAP as well as PVR in
these patients [17], suggesting that recurrent exposure to nocturnal hypercapnia is a treatable
causality of daytime PH. Therefore, we anticipate that nocturnal hypercapnia among PAH
patients may constitute a significant pathogenic role in the development of PAP escalation,
and its normalization is a possible strategy for treatment of PAH.
In the present study, we found a significant positive correlation between mean PtcCO2 lev-
els at night and CO as well as CI. The increase in CO is a fundamental factor in the elevation of
PAP; therefore it is suggested that nocturnal hypercapnia is associated with an increase in
PAP. On the other hand, a correlation between mean PtcCO2 at night and mean PAP or PVR
was not apparent. We propose two possible interpretations of these data. One is that nocturnal
hypercapnia increases CO without affecting PAP or PVR. The other interpretation is that noc-
turnal hypercapnia induces an increase in CO and PVR, but that in these patients the PVR ele-
vation was masked by medication. We found that the usage of epoprostenol infusions was
relatively frequent and also that the dose was higher in the study patients with nocturnal
hypercapnia, which could have lowered PVR. A previous study showed that CO was well cor-
related lineally with CO2 production (40). Therefore, patients with high CO would have higher
CO2 production than patients with relative low CO. In addition to low lung function (Table 2),
the difference in CO2 production related to CO would partly contribute to a significant eleva-
tion in mean and max PtcCO2 in the patients with high CO: the patients with nocturnal hyper-
capnia (Tables 2 and 3). Because the current study could not dissect the contribution of
nocturnal hypercapnia to the hemodynamic status in PAH patients without the confounding
effect of medications, a future study can be expected to investigate whether nocturnal hyper-
capnia affects PAP or PVR. In addition, dynamic changes of PAP in parallel with the levels of
PtcCO2 were reported [13, 16]. Nocturnal hypercapnia was specifically observed during sleep,
therefore a future study focusing on hemodynamics during sleep is expected.
Although the data sample was small, it is notable that as many as 46.2% (6/13) of PAH
patients overall and 83.3% (5/6) of IPAH patients had nocturnal hypercapnia. We suppose that
this high rate has been overlooked because these patients rarely manifest daytime hypercapnia.
In general, the condition of PAH patients waiting for lung transplantation is refractory against
full treatment with currently available medications. Considering that nocturnal hypercapnia is
treatable with NIV [17, 31], we would consider that NIV during sleep could be a novel option
to treat these patients. Further investigation of the use of NIV in such patients is needed.
This study has several limitations. First, due to its retrospective nature, disease severity,
treatment procedures and comorbid diseases were not controlled for. In addition, because of
the small number of study patients, we could not perform multivariate analysis to adjust for
these variables. Second, the number of study patients was scant; thus the power to detect differ-
ences between groups may not be sufficient. Third, a detailed evaluation of sleep status (e.g.
polysomnography) was not performed; therefore, precise events occurring in PAH patients
during sleep were not analyzed. Especially, further investigations are required to reveal the
pathophysiology affecting IPAH patients that contributed to the high frequency of nocturnal
hypercapnia in this group.
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In spite of these limitations, we for the first time reported that nocturnal hypercapnia was
observed in nearly half of PAH patients and in the majority of IPAH patients who were consid-
ered for lung transplantation. Also revealed were possible correlations between nocturnal
hypercapnia and impaired pulmonary function or altered hemodynamic status in the daytime.
Further studies are needed to investigate hemodynamics during sleep and to dissect the direct
effect of nocturnal hypercapnia on PAP or PVR and to evaluate whether the normalization of
nocturnal hypercapnia has therapeutic significance for PAH patients.
Supporting information
S1 Fig. Representative TOSCA results for patients with nocturnal hypercapnia. (A)
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patient with IPAH. The intervals between the bold lines were analyzed. IPAH: idiopathic pul-
monary arterial hypertension.
(TIF)
S1 Dataset. The dataset used for the analyses in this study.
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